Eli Lilly stock has traded as a referendum on the GLP-1 class through 2026. The April 30 Q1 print drove a 6.11% gain on May 1 as Mounjaro's $8.66B (+125%) and Zepbound's $4.16B (+80%) anchored a guidance raise to $82–85B. The May 4 Foundayo hepatic-failure FAERS report knocked shares down ~3% premarket before Lilly's Global Patient Safety response and an RBC 'baseline noise' defense restored the trade.
By May 5–6, Wall Street had repriced to the upside. Barclays lifted its target to $1,400 on tirzepatide momentum, Cantor Fitzgerald to $1,230, BofA to $1,294 — and the 19-firm analyst consensus settled at $1,228, implying ~24% 12-month upside on a $966 base. The mix of drivers: tirzepatide volume growth, the seven retatrutide TRIUMPH Phase 3 readouts due in 2026, the Foundayo small-molecule manufacturing economics, and the wide gap to Pfizer MariTide and Novo CagriSema higher-dose readouts in 2027.
Stories here cover earnings reactions, analyst calls, and the share-price moves that follow them. See #eli-lilly, #foundayo, and #tirzepatide.
Sector stock reaction across May 12-13: Novo Nordisk ADRs popped roughly 6% premarket May 12 on the early-responder + women's-data combination and the OASIS 4 mobility analyses; Eli Lilly traded flat as the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN dual publication confirmed expected maintenance positioning rather than producing fresh upside surprises. Analysts noted the broader 'long-term treatment' thesis — that GLP-1 obesity drugs are chronic-disease medications, not short courses — got concrete trial backing this week between SURMOUNT-MAINTAIN, ATTAIN-MAINTAIN, and STEP UP early-responder analyses. The week's narrative shift sets up the May 14-15 ECO Day 3+4 cycle and the May 29-June 2 ASCO 2026 meeting in Chicago — where peptide-drug conjugates (Bicycle BT8009, Avacta AVA6000, Pfizer FAP-Dox) take the next round of clinical-data spotlights.
Barclays analyst Emily Field raised her price target on Eli Lilly to $1,400 from $1,350 May 5 and reiterated an Overweight rating, citing tirzepatide momentum continuing to outpace the GLP-1 class and easing concerns around the Foundayo launch trajectory. LLY stock had recovered roughly 11% off the May 4 Foundayo FAERS-driven dip to about $966 by mid-week. Barclays simultaneously trimmed its 2026 Foundayo revenue estimate to approximately $1B (vs. ~$1.4B consensus) on the early IQVIA gap to Wegovy pill, but the higher headline target reflects confidence that Mounjaro and Zepbound's volume growth more than absorbs Foundayo's slower start.
Multiple Wall Street firms raised LLY price targets in the May 5–6 window. Cantor Fitzgerald lifted its target to $1,230, BofA to $1,294, and the broader analyst consensus by 19 firms now sits at $1,228 (24.15% upside over 12 months) per the May 6 update, with a Buy consensus rating. The driver: tirzepatide's Q1 +125% global growth, the Mounjaro/Zepbound volume re-rating, the May 1 stock recovery from the Foundayo hepatic-failure FAERS report, and Lilly's response that no DILI signal exists across the 11,000-patient ACHIEVE+ATTAIN program. RBC Capital framed the FAERS event as 'baseline noise.'
Eli Lilly stock has gained roughly 11% over the past week, recovering from the May 4 Foundayo hepatic-failure FAERS report-driven 3% premarket dip and consolidating gains from the April 30 Q1 beat. Per the May 6 analyst consensus across 19 covering firms, LLY now carries an average 12-month price target of $1,228 — implying 24.15% upside from current $966 — with a Buy consensus rating. The recovery framework: tirzepatide volume (+125% global Q1 growth) anchors the floor, retatrutide TRIUMPH program (seven Phase 3 readouts due in 2026) anchors the upside, the small-molecule manufacturing economics of Foundayo offset peptide CDMO bottlenecks, and Pfizer's MariTide/MET-097i and Novo's CagriSema higher-dose program don't read out until 2027.
RBC Capital reiterated its Outperform rating on Eli Lilly May 4 with the framing 'baseline noise, not a mechanistic safety signal,' and put the single Foundayo case in context against the broader GLP-1 class hepatic failure tally: Mounjaro 30 cases, Zepbound 2, Ozempic 33, Wegovy 15. Other Street analysts followed similar reasoning. The defense rests on the 11,000-patient clinical program and the absence of any DILI signal across two years of follow-up. The framing matters because the launch trajectory for Foundayo had already been challenged by IQVIA tracker data showing the Wegovy pill running roughly 20× ahead in retail prescriptions; a sustained safety overhang would compound the commercial pressure.
Eli Lilly shares climbed 6.11% on May 1 as the market digested the company's Q1 2026 print: $19.8B in revenue (+56% YoY), Mounjaro at $8.66B globally (+125%), Zepbound at $4.16B in U.S. sales (+80%), and reported EPS of $8.26 versus the $6.97 consensus. Multiple sell-side analysts revised price targets higher and reiterated or upgraded ratings, citing the strength of the cardiometabolic franchise and the $2 billion guidance raise to $82–85B. The reaction crystallized Lilly's positioning as the GLP-1 leader heading into Novo's May 6 Q1 print.